Immunotherapy for prostate cancer: walk, don't run.
Drake
Charles G
CG
D000135:Acid Phosphatase; D000230:Adenocarcinoma / Q000201:enzymology / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007271:Injections, Intradermal; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D017027:Protein Tyrosine Phosphatases / Q000276:immunology; D011994:Recombinant Proteins; D013997:Time Factors; D014020:Tissue Extracts / Q000627:therapeutic use; D016896:Treatment Outcome; D019444:Vaccines, DNA / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D011994:Recombinant Proteins; D014020:Tissue Extracts; D019444:Vaccines, DNA; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C511774:sipuleucel-T; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases